pp 1-29 | Cite as

Achieving High Levels of Selectivity for Kinase Inhibitors

  • Laurent SchioEmail author
  • Herve Minoux
Part of the Topics in Medicinal Chemistry book series


Kinase inhibitors have emerged over the last two decades as one of the most prolific therapeutic classes of agents to reach clinical trials and to obtain marketing approval, mainly for oncology. We describe here the methodologies that we performed for hit and lead finding in the context of four internal projects to identify selective inhibitors for development or preclinical pharmacological evaluation.


Kinase inhibitors Ligands Oncology Protein conformations Selectivity Targeted therapy 


Compliance with Ethical Standards

Conflict of Interest: All authors are employees of Sanofi R&D and may hold stock in the same. All authors declare no conflict of interest.

Funding: All studies were funded only by Sanofi R&D.

Ethical Approval: This chapter does not contain any studies with human participants or animals performed by any of the authors.

Informed Consent: No human studies are reported; no informed consent required.


  1. 1.
    Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912–1934Google Scholar
  2. 2.
    Roskoski R (2018) FDA-approved protein kinase inhibitors.
  3. 3.
    Monoclonal antibodies approved by the EMA and FDA for therapeutic use.
  4. 4.
    Giordano S (2008) Curr Med Chem 15:422–432Google Scholar
  5. 5.
    Serrano C, George S (2014) Recent advances in the treatment of gastrointestinal stromal tumors. Ther Adv Med Oncol 6:115–127Google Scholar
  6. 6.
    Yan L, Rosen N, Arteaga C (2011) Targeted cancer therapies. Chin J Cancer 30:1–4Google Scholar
  7. 7.
    Jänne PA, Gray N, Settleman J (2009) Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov 8:709–723Google Scholar
  8. 8.
    Knight ZA, Shokat KM (2005) Features of selective kinase inhibitors. Chem Biol 12:621–637Google Scholar
  9. 9.
    Schwartz PA, Murray BW (2011) Protein kinase biochemistry and drug discovery. Bioorg Chem 39:192–210Google Scholar
  10. 10.
    Morphy R (2010) Selectively nonselective kinase inhibition: striking the right balance. J Med Chem 53:1413–1437Google Scholar
  11. 11.
    Zhao Y, Adjei AA (2014) The clinical development of MEK inhibitors. Nat Rev Clin Oncol 11:385–400Google Scholar
  12. 12.
    Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz Jr LA, Kinzler KW (2013) Cancer genome landscapes. Science 339:1546–1558Google Scholar
  13. 13.
    Sullivan I, Planchard D (2017) Next-generation EGFR tyrosine kinase inhibitors for treating EGFR-mutant lung Cancer beyond first line. Front Med.
  14. 14.
    Holderfield M, Deuker MM, McCormick F, McMahon M (2014) Targeting RAF kinases for cancer therapy: BRAF mutated melanoma and beyond. Nat Rev Cancer 14:455–467Google Scholar
  15. 15.
    Knighton DR et al (1991) Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253:407–414Google Scholar
  16. 16.
    Kornev AP, Haste NM, Taylor SS, Ten Eyck LF (2006) Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. PNAS 103:17783–17788Google Scholar
  17. 17.
    McClendona CL, Kornevc AP, Gilsonb M, Taylor SS (2014) Dynamic architecture of a protein kinase. PNAS 111:E4623–E4631Google Scholar
  18. 18.
    Brewer MR, Yun CH, Lai D, Lemmon MA, Eck MJ, Pao W (2013) Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. PNAS 110:E3595–E3604Google Scholar
  19. 19.
    Fratev FF, Jónsdóttir SO (2009) An in silico study of the molecular basis of B-RAF activation and conformational stability. BMC Struct Biol 9:1–17Google Scholar
  20. 20.
    Echeverria I, Liu Y, Gabelli SB, Amzel LM (2015) Oncogenic mutations weaken the interactions that stabilize the p110a-p85a heterodimer in phosphatidylinositol 3-kinase α. FEBS J 282:3528–3542Google Scholar
  21. 21.
    Peng W, Thomas EN, Mads HC (2015) FDA-approved small-molecule kinase inhibitors. Trends Pharmacol Sci 36:422–439Google Scholar
  22. 22.
    Wu P, Nielsen TE, Clausen MH (2016) Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. Drug Discov Today 21:5–10Google Scholar
  23. 23.
    Martin E, Mukherjee P (2012) Kinase-kernel models: accurate in silico screening of 4 million compounds across the entire human kinome. J Chem Inf Model 52:156–170Google Scholar
  24. 24.
    Taylor SS, Kornev PA (2011) Protein kinases: evolution of dynamic regulatory proteins. Trends Biochem Sci 36:65–77Google Scholar
  25. 25.
    Zarrinkar PP et al (2008) A quantitative analysis of kinase inhibitor selectivity. Nat Biotech 26:127–132Google Scholar
  26. 26.
    Jacobs MD, Caron PR, Hare BJ (2008) Classifying protein kinase structures guides use of ligand-selectivity profiles to predict inactive conformations: structure of lck/imatinib complex. Proteins 70:1451–1460Google Scholar
  27. 27.
    Zarrinkar PP et al (2011) Comprehensive analysis of kinase inhibitor selectivity. Nat Biotech 29:1046–1051Google Scholar
  28. 28.
    Fabbro D, Cowan-Jacob SW, Moebitz H (2015) Ten things you should know about protein kinases. Br J Pharmacol 172:2675–2700Google Scholar
  29. 29.
    Palmieri L, Rastelli G (2013) αC helix displacement as a general approach for allosteric modulation of protein kinases. Drug Discov Today 18:407–414Google Scholar
  30. 30.
    Gilmer TM (2008) Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by Lapatinib. Cancer Res 68:571–579Google Scholar
  31. 31.
    Hochegger H, Hegarat N, Pereira-Leal JB (2013) Aurora at the pole and equator: overlapping functions of Aurora kinases in the mitotic spindle. Open Biol.
  32. 32.
    Saya H (2002) Roles of aurora A kinase in mitotic entry and G2 checkpoint in mammalian cells. Genes Cells 7:1173–1182Google Scholar
  33. 33.
    Lampson MA, Cheeseman IM (2011) Sensing centromere tension: aurora B and the regulation of kinetochore function. Trends Cell Biol 21:133–140Google Scholar
  34. 34.
    Quartuccio SM, Schindler K (2015) Functions of Aurora kinase C in meiosis and cancer. Front Cell Dev Biol.
  35. 35.
    Katayama H, Brinkley WR, Sen S (2003) The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 22:451–464Google Scholar
  36. 36.
    Goldenson B, Crispino JD (2015) The aurora kinases in cell cycle and leukemia. Oncogene 34:537–545Google Scholar
  37. 37.
    Tang A, Gao K, Chu L, Zhang R, Yang J, Zheng J (2017) Aurora kinases: novel therapy targets in cancers. Oncotarget 8(14):23937–23954Google Scholar
  38. 38.
    Keen N, Taylor S (2004) Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer 4:927–936Google Scholar
  39. 39.
    Carry JC, Clerc F, Minoux H et al (2015) SAR156497, an exquisitely selective inhibitor of aurora kinases. J Med Chem 58:362–375Google Scholar
  40. 40.
    Roskoski R (2016) Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes. Pharmacol Res 103:26–48Google Scholar
  41. 41.
    Tong M, Seeliger MA (2015) Targeting conformational plasticity of protein kinases. ACS Chem Biol 10:190–200Google Scholar
  42. 42.
    Organ SL, Tsao MS (2011) An overview of the c-MET signaling pathway. Ther Adv Med Oncol 3(1 Suppl):S7–S19Google Scholar
  43. 43.
    Zhang J, Babic A (2016) Regulation of the MET oncogene: molecular mechanisms. Carcinogenesis 37:345–355Google Scholar
  44. 44.
    Tovar EA, Graveel CR (2017) MET in human cancer: germline and somatic mutations. Ann Trans Med 5(10):205. Scholar
  45. 45.
    Dixit A, Torkamani A, Schork NJ, Verkhivker G (2009) Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability. Biophys J 96:858–874Google Scholar
  46. 46.
    Xu J, Wang J, Zhang S (2017) Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer. Oncotarget 8(52):90557–90578Google Scholar
  47. 47.
    Soria JC et al (2012) ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur J Cancer 48:961–973Google Scholar
  48. 48.
    Mo HN, Liu P (2017) Targeting MET in cancer therapy. Chronic Dis Trans Med 3(3):148–153Google Scholar
  49. 49.
    Schio L, Nemecek C, Ugolini T et al (2012) SAR125844: a potent and selective ATP-competitive inhibitor of MET kinase. Cancer Res 72(8, Suppl.1):2911Google Scholar
  50. 50.
    Schio L et al (2016) Discovery, pharmacokinetic and pharmacological properties of the potent and selective MET kinase inhibitor, 1-{6-[6-(4-Fluoro-phenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]-benzothiazol-2-yl}-3-(2-morpholin-4-yl-ethyl)-urea (SAR125844) J. Med Chem 59:7066–7074Google Scholar
  51. 51.
    Romano G, Giordano A (2008) Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases. Cell Cycle 7(23):3664–3668Google Scholar
  52. 52.
    Dussault I, Bellon SF (2009) From concept to reality: the long road to c-met and RON receptor tyrosine kinase inhibitors for the treatment of Cancer. Anti Cancer Agents Med Chem 9:221–229Google Scholar
  53. 53.
    Komoto J, Yamada T, Takata Y, Markham GD, Takusagawa F (2004) Crystal structure of the S-Adenosylmethionine Synthetase ternary complex: a novel catalytic mechanism of S-Adenosylmethionine synthesis from ATP and met. Biochemistry 43:1821–1831Google Scholar
  54. 54.
    Eathiraj S et al (2011) Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human Mesenchymal-epithelial transition factor (c-met) protein autophosphorylation by ARQ 197. J Biol Chem 286(23):20666–20676Google Scholar
  55. 55.
    Coumaran E, Goulaouic H (2015) Selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified Cancer. Mol Cancer Ther 14(2):384–394Google Scholar
  56. 56.
    Angevin E et al (2017) A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification. Eur J Cancer 87:131–139Google Scholar
  57. 57.
    Lindmo K, Stenmark H (2006) Regulation of membrane traffic by phosphoinositide 3-kinases. J Cell Sci 119:605–614Google Scholar
  58. 58.
    Backer JM (2016) The intricate regulation and complex functions of the class III phosphoinositide 3-kinase Vps34. Biochem J 473(15):2251–2271Google Scholar
  59. 59.
    Stjepanovic G, Baskaran S, Mary G, Lin MG, Hurley JH (2017) Unveiling the role of VPS34 kinase domain dynamics in regulation of the autophagic PI3K complex. Mol Cell Oncol 4(6):e1367873Google Scholar
  60. 60.
    Bilanges B (2017) Vps34 PI3-kinase inactivation enhances insulin sensitivity through reprogramming of mitochondrial metabolism. Nat Commun 8(1):1804. Scholar
  61. 61.
    Honda A et al (2016) Potent, selective, and orally bioavailable inhibitors of VPS34 provide chemical tools to modulate autophagy in vivo. ACS Med Chem Lett 7:72–76Google Scholar
  62. 62.
    Pasquier B (2016) Autophagy inhibitors. Cell Mol Life Sci 73:985–1001Google Scholar
  63. 63.
    Peppard JV, Ronan B, Pasquier B (2014) Identifying small molecules which inhibit autophagy: a phenotypic screen using image-based high-content cell analysis. Curr Chem Genom Trans Med 8(Suppl-1, M2):3–15Google Scholar
  64. 64.
    Pasquier B, El-Ahmad Y, Filoche-Rommé B et al (2015) Discovery of (2S)-8-[(3R)-3-Methylmorpholin-4-yl]-1-(3-methyl-2-oxobutyl)-2-(trifluoromethyl)-3,4-dihydro-2Hpyrimido[1,2-a]pyrimidin-6-one: a novel potent and selective inhibitor of Vps34 for the treatment of solid tumors. J Med Chem 58:376–400Google Scholar
  65. 65.
    Pasquier B, Goulaouic H et al (2014) A highly potent and selective Vps34 inhibitor alters vesicle trafficking and autophagy. Nat Chem Biol 10:1013–1019Google Scholar
  66. 66.
    Pasquier B (2015) SAR405, a PIK3C3/Vps34 inhibitor that prevents autophagy and synergizes with mTOR inhibition in tumor cells. Autophagy 11(4):725–726Google Scholar
  67. 67.
    Kriplani N, Hermida MA, Brown ER, Leslie NR (2015) Class I PI3-kinases: function and evolution. Adv Biol Regulation 59:53–64Google Scholar
  68. 68.
    Vadas O, Burke JE, Zhang X, Berndt A, Williams RL (2011) Structural basis for activation and inhibition of class I Phosphoinositide 3-kinases. Sci Signal 4(195):re2Google Scholar
  69. 69.
    Yu JSL, Cui W (2016) Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signaling in pluripotency and cell fate determination. Development 143:3050–3060Google Scholar
  70. 70.
    Millis SZ, Ikeda S, Reddy S, Gatalica Z, Kurzrock R (2016) Landscape of Phosphatidylinositol-3-kinase pathway alterations across 19784 diverse solid tumors. JAMA Oncol 2(12):1565–1573Google Scholar
  71. 71.
    Lengauer C et al (2008) PTEN-deficient cancers depend on PIK3CB. Proc Natl Acad Sci U S A 105(35):13057–13062Google Scholar
  72. 72.
    Dillon LM, Miller TW (2014) Therapeutic targeting of cancers with loss of PTEN function. Curr Drug Targets 15(1):65–79Google Scholar
  73. 73.
    Greenwell IB, Ip A, Cohen JB (2017) PI3K inhibitors: understanding toxicity mechanisms and management. Oncology (Williston Park) 31(11):821–828Google Scholar
  74. 74.
    Williams RL (2011) Structure of lipid kinase p110b/p85b elucidates an unusual SH2-domain-mediated inhibitory mechanism. Mol Cell 41:567–578Google Scholar
  75. 75.
    Metz A, Ciglia E, Gohlke H (2012) Modulating protein-protein interactions: from structural determinants of binding to Druggability prediction to application. Curr Pharm Des 18:4630–4647Google Scholar
  76. 76.
    Vlahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3 kinase, 2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one (LY294002). J Biol Chem 269(7):5241–5248Google Scholar
  77. 77.
    Certal V, Halley F, Virone-Oddos A et al (2012) Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers. J Med Chem 55:4788–4805Google Scholar
  78. 78.
    Knight ZA, Williams RL, Shokat KM (2006) A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125(4):733–747Google Scholar
  79. 79.
    Certal V, Carry JC, Frank Halley F et al (2014) Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and Tensin homologue (PTEN)-deficient cancers. J Med Chem 57:903–992Google Scholar
  80. 80.
    Somoza JR et al (2015) Structural, biochemical, and biophysical characterization of Idelalisib binding to Phosphoinositide 3-kinase δ. JBC 290(13):8439–8446Google Scholar
  81. 81.
    Robinson DD. WaterMap – theory and practical applications.
  82. 82.
    Wang L, Berne BJ, Friesner RA (2011) Ligand binding to protein-binding pockets with wet and dry regions. PNAS 108(4):1326–1330Google Scholar
  83. 83.
    Robinson D, Bertrand T, Carry JC et al (2016) Differential water thermodynamics determine PI3K-Beta/Delta selectivity for solvent-exposed ligand modifications. J Chem Inf Model 56:886–894Google Scholar
  84. 84.
    Demers B et al (2018) First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors. Cancer 124(2):315–324Google Scholar
  85. 85.
    Wu P, Clausen MH, Nielsen TE (2015) Allosteric small-molecule kinase inhibitors. Pharmacol Ther 156:59–68Google Scholar
  86. 86.
    Cowan-Jacob SW, Jahnke W, Knapp S (2014) Novel approaches for targeting kinases: allosteric inhibition, allosteric activation and pseudokinases. Future Med Chem 6(5):541–561Google Scholar
  87. 87.
    Cheng Y et al (2012) MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther 11(1):154–164Google Scholar
  88. 88.
    Simard JR, Rauh R (2014) FLiK: a direct-binding assay for the identification and kinetic characterization of stabilizers of inactive kinase conformations. Methods Enzymol 548:147–171Google Scholar
  89. 89.
    Leis S, Schneider S, Zacharias M (2010) In Silico prediction of binding sites on proteins. Curr Med Chem 17:1550–1562Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Integrated Drug Discovery, SanofiVitry-sur-SeineFrance

Personalised recommendations